Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model
Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model have?
Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model has 25 citations in the OpenAlex counts ScholarIQ stores.
When was Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model published?
Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model has 2018 year in the ScholarIQ index.
What is the open-access status of Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model?
Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model has bronze oa status in the ScholarIQ index.
What is the DOI of Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model?
The DOI for Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model is on the source record.
What is the PMID of Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model?
The PMID for Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model is on the source record.
What is the OpenAlex record for Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model?
The OpenAlex for Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model is on the source record.